GU Cancers 2019 | Treatment with abiraterone acetate without steroids in mCRPC
Abiraterone acetate has shown clinical effectiveness and is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC). However, due to the drug’s inhibitory effect on androgen biosynthesis, it is often administered with glucocorticoids and is associated with mineralocorticoid toxicity. Rana McKay, MD, of the University of California San Diego, San Diego, CA, discusses her group’s Phase II, single-arm trial that investigated the safety of abiraterone acetate without glucocorticoids in mCRPC patients. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up